BioHarvest Sciences Inc. (BHST) Q3 2024 Earnings Call Transcript Summary
BioHarvest Sciences Inc. (BHST) Q3 2024 Earnings Call Transcript Summary
Net losses totaled $2.7 million, or $0.16 per basic and diluted share, while adjusted EBITDA loss totaled $2 million.The following is a summary of the BioHarvest Sciences Inc. (BHST) Q3 2024 Earnings Call Transcript:
以下是BioHarvest Sciences Inc. (BHST) 2024年第三季度业绩会摘录的总结：
Financial Performance:
财务表现：
BioHarvest Sciences reported Q3 2024 revenue of $6.5 million, a 101% increase from the previous year, driven by strong VINIA sales.
Gross profit margin increased to 57%, reflecting a 1,200 basis point improvement year-over-year primarily due to increased manufacturing scale, improved yields, and cost reduction in downstream packaging.
Net losses totaled $2.7 million, or $0.16 per basic and diluted share, while adjusted EBITDA loss totaled $2 million.
BioHarvest Sciences报告2024年第三季度营业收入为650万，较去年增长101%，主要受益于VINIA销售强劲。
毛利率提高至57%，同比提高1200个基点，主要得益于制造业-半导体规模的扩大、产量提升和下游-脑机包装成本的降低。
净亏损总计270万，或每股基本和摊薄亏损0.16美元，调整后的息税折旧摊销前亏损总计200万。
Business Progress:
业务进展：
Continued growth in the VINIA subscriber base and successful launch of VINIA SuperFood functional tea lineup. Anticipated launches include VINIA Pro chews and hydration solutions targeting active consumers.
Expansion into additional markets with regulatory efforts underway, and a significant focus on digitization to optimize production and gross margin outcomes.
Development of the CDMO business unit, focusing on contract development and manufacturing of botanically synthesized molecules.
VINIA订阅用户基础持续增长，成功推出VINIA SuperFood功能性茶系列。预计推出的产品包括针对活跃消费的VINIA Pro咀嚼剂和补水解决方案。
在监管努力推进的情况下，向额外市场扩展，并重点推进数字化，以优化生产和毛利率结果。
发展CDMO业务部门，专注于植物合成分子的合同开发和制造。
Opportunities:
机会：
Expansion into the Canadian market following recent regulatory approval, with further exploration into other strategic markets.
Broadening the product portfolio in direct-to-consumer business by introducing new VINIA Inside products such as functional coffees and teas.
Entry into hydration and wellness categories, leveraging superior science and clinical trial-backed efficacy.
在最近获得监管批准后，扩展到加拿大市场，并进一步探索其他战略市场。
通过引入新的VINIA Inside产品，如功能性咖啡和茶，拓宽直消业务的产品组合。
进入水分补充和健康类别，利用卓越的科学和临床试验支持的功效。
Risks:
风险：
Challenges and delays related to the sourcing of critical raw materials for their CDMO business unit could impact project timelines and revenue recognition from these engagements.
与其CDMO业务部门关键原材料采购相关的挑战和延迟可能会影响项目时间表和这些项目的营业收入确认。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的详情，请参阅投资人关系网站。本文仅供投资者参考，不作任何指引或建议。
译文内容由第三方软件翻译。
